Patents by Inventor Satoshi Minakami

Satoshi Minakami has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210000817
    Abstract: A tableted pharmaceutical composition contains nalfurafine or a pharmaceutically acceptable acid addition salt thereof and is excellent in formability and quality control of related substances. The tableted pharmaceutical composition includes nalfurafine or a pharmaceutically acceptable acid addition salt thereof, a binder component, and a carrier, wherein the above mentioned nalfurafine or a pharmaceutically acceptable acid addition salt thereof is contained in an amount of 0.1 to 10 ?g, and the weight of the above mentioned binder component is 100,000 to 2,000,000 weight % based on the weight of the above mentioned nalfurafine or a pharmaceutically acceptable acid addition salt thereof and 5 to 20 weight % based on the total weight of the resulting pharmaceutical composition, or 20,000 to 500,000 weight % and 1 to 5 weight % based on the total weight of the resulting pharmaceutical composition.
    Type: Application
    Filed: March 30, 2018
    Publication date: January 7, 2021
    Inventors: Satoshi Minakami, Suguru Takaki, Kotoe Ohta, Yasuhide Horiuchi
  • Publication number: 20190262270
    Abstract: A solid preparation includes a 4,5-epoxymorphinan derivative or a pharmaceutically acceptable acid addition salt thereof, which is stable to light even without light shielding coating. The solid preparation includes an active ingredient composed of a 4,5-epoxymorphinan derivative or a pharmaceutically acceptable acid addition salt thereof, and one or more stabilizing agents selected from the group consisting of n-propyl gallate, sodium hydrogensulfite, dibutylhydroxytoluene, butylhydroxyanisole, tocopherol and D-isoascorbic acid, wherein the amount of the above active ingredient is 0.00001 to 0.01% by weight of the solid preparation, and the amount of the above stabilizing agent is 0.005 to 5% by weight of the solid preparation.
    Type: Application
    Filed: July 28, 2017
    Publication date: August 29, 2019
    Applicant: Toray Industries, Inc.
    Inventors: Suguru TAKAKI, Satoshi MINAKAMI, Kotoe OHTA
  • Publication number: 20180338927
    Abstract: In a system where phase separation into two phases occurs when an ether cellulose derivative (A), a polymer (B) different from the ether cellulose derivative (A), and an alcohol solvent (C) are mixed together, the two phases including a solution phase mainly containing the ether cellulose derivative (A) and a solution phase mainly containing the polymer (B), the two separated phases containing approximately the same solvent, an emulsion is formed and brought into contact with a poor solvent (D) to provide an ether cellulose derivative microparticle having an average particle diameter of 1 to 1,000 ?m, a linseed oil absorption of 50 to 1,000 mL/100 g, and an average surface pore size of 0.05 to 5 ?m.
    Type: Application
    Filed: October 26, 2016
    Publication date: November 29, 2018
    Inventors: Takahiko Otsubo, Kotoe Ohta, Yuji Echigo, Hiroshi Takezaki, Suguru Takaki, Satoshi Minakami, Akinori Ito, Hisashi Miyama
  • Patent number: 9084817
    Abstract: A chemically stable oral preparation with an excellent dissolution property comprising as an effective ingredient a specific morphinan derivative or a pharmaceutically acceptable acid addition salt thereof is disclosed. The oral preparation according to the present invention comprises a specific morphinan derivative or a pharmaceutically acceptable acid addition salt thereof as an effective ingredient and an organic acid, wherein 1 g of said organic acid requires not less than 30 mL of water to dissolve in at 20° C. The method for improving dissolution property and chemical stability of an oral preparation according to the present invention comprises incorporating an organic acid in the oral preparation comprising as an effective ingredient a specific morphinan derivative or a pharmaceutically acceptable acid addition salt thereof, wherein 1 g of said organic acid requires not less than 30 mL of water to dissolve in at 20° C.
    Type: Grant
    Filed: May 20, 2008
    Date of Patent: July 21, 2015
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Kotoe Ohta, Satoshi Minakami, Hiroyuki Tokumitsu
  • Publication number: 20100215750
    Abstract: A chemically stable oral preparation with an excellent dissolution property comprising as an effective ingredient a specific morphinan derivative or a pharmaceutically acceptable acid addition salt thereof is disclosed. The oral preparation according to the present invention comprises a specific morphinan derivative or a pharmaceutically acceptable acid addition salt thereof as an effective ingredient and an organic acid, wherein 1 g of said organic acid requires not less than 30 mL of water to dissolve in at 20° C. The method for improving dissolution property and chemical stability of an oral preparation according to the present invention comprises incorporating an organic acid in the oral preparation comprising as an effective ingredient a specific morphinan derivative or a pharmaceutically acceptable acid addition salt thereof, wherein 1 g of said organic acid requires not less than 30 mL of water to dissolve in at 20° C.
    Type: Application
    Filed: May 20, 2008
    Publication date: August 26, 2010
    Applicant: Toray Industries, Inc.
    Inventors: Kotoe Ohta, Satoshi Minakami, Hiroyuki Tokumitsu
  • Publication number: 20100189679
    Abstract: A cross-linked polyallylamine or an acid addition salt thereof has both high phosphate adsorption capability and low degree of swelling, and a medical use thereof. The cross-linked polyallylamine or an acid addition salt thereof is obtained by copolymerization of allylammonium dihydrogen phosphate with an acid addition salt of N,N?-diallyl-1,3-diaminopropane in an amount of 5 to 25 mol % with respect to the amount of the allylammonium dihydrogen phosphate, the cross-linked polyallylamine or an acid addition salt thereof having a phosphate adsorption capacity of 2.7 to 5.0 mmol/g; and a degree of swelling of 2.0 to 5.0. The cross-linked polyallylamine or an acid addition salt thereof is useful as a therapeutic or prophylactic agent for hyperphosphatemia.
    Type: Application
    Filed: July 10, 2008
    Publication date: July 29, 2010
    Applicant: TORAY INDUSTRIES, INC.
    Inventors: Atsushi Inoue, Kazuharu Suyama, Satoshi Minakami, Mitsuko Miyamoto, Shoichi Itaba